


Image

02-25-04

1635



EXPRESS MAIL: EV 333998 239US

02/23/2004

**RESPONSE**

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Attorney Docket No.	CELL-017
Confirmation No.	3927
First Named Inventor	YU, DE-CHAO
Application Number	09/814,357
Filing Date	March 21, 2001
Group Art Unit	1635
Examiner Name	WHITEMAN, BRIAN
Title: "Methods of Treating Neoplasia with Combinations of Target Cell-Specific Adenovirus, Chemotherapy and Radiation"	

Sir:

This amendment is responsive to the Office Action dated December 10, 2003 for which a three-month period for response was given making this response due on or before March 10, 2004. Please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 117, lines 4-15, please replace with the following rewritten paragraph:

A synergistic effect was also observed in the combination treatment of xenograft tumors with CV787 and docetaxel. Results from LNCaP prostate tumor xenografts treated with CV787 and docetaxel, both administered intravenously: in the combination treatment group, animals were intravenously injected with docetaxel (5.0 mg/kg) on day 2, day 5 and day 8, following a single intravenous injection of CV787 ( $1 \times 10^{10}$  particles per animal) on day 1. Both CV787 and docetaxel appear to be effective in producing stabilization of tumor growth in the LNCaP mouse model, whereas a combination of the two produce a complete regression within 5 weeks (Figure 6-13). Analysis on fractional tumor volume, indicated a synergistic effect between CV787 and docetaxel in LNCaP xenografts. For example, on day 42, CV787 and docetaxel combination group showed a 6.4-fold higher inhibition of tumor growth over an additive effect.